Meet Your ETF AI Analyst
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the scheduling of its 2025 second extraordinary general meeting (EGM) to be held on December 2, 2025, in Shanghai. The primary agenda is to elect Mr. Liu Yi as an executive director. This meeting reflects the company’s ongoing efforts to strengthen its leadership structure, which could have implications for its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The…
